Autoimmune Gastrointestinal Dysmotility Global Market Report 2025

Name: Autoimmune Gastrointestinal Dysmotility Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Download Sample Buy Report

Global Autoimmune Gastrointestinal Dysmotility Market Report 2025

Autoimmune Gastrointestinal Dysmotility Global Market Report 2025 - By Treatment Type (Medications, Surgical Interventions, Dietary Management, Physical Therapy), By Drug Class (Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics), By Disease Type (Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels), By End User (Hospitals, Clinics, Home Care Settings, Research Institutions) - Market Size, Trends, And Global Forecast 2025-2034

Autoimmune Gastrointestinal Dysmotility Global Market Report 2025

Report Price : $4490.00 | Pages : 200 | Published : June 2025 | Delivery Time: 2-3 business days Info | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Autoimmune Gastrointestinal Dysmotility Global Market Report 2025

Proud Members Of

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Autoimmune Gastrointestinal Dysmotility Market?

Autoimmune gastrointestinal dysmotility (AGID) is a rare disorder where the immune system attacks the nerves controlling digestive tract movement. This disorder leads to slowed or abnormal motility, causing symptoms such as nausea, bloating, constipation, or intestinal blockage. Autoimmune gastrointestinal dysmotility (AGID) is often associated with autoimmune conditions or may occur as a paraneoplastic syndrome.

The main treatment types for autoimmune gastrointestinal dysmotility include medications, surgical interventions, dietary management, and physical therapy. Medications are prescribed to help manage autoimmune gastrointestinal dysmotility by reducing inflammation and improving digestive tract motility. The drug classes include prokinetic agents, anti-inflammatory drugs, immunosuppressive drugs, and antibiotics. The diseases associated with autoimmune gastrointestinal dysmotility include gastroparesis, chronic intestinal pseudo-obstruction (CIPO), functional dyspepsia, irritable bowel syndrome (IBS), and celiac disease. These drugs are distributed through various channels such as hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. They are used by various end-users, including hospitals, clinics, home care settings, and research institutions.

Autoimmune Gastrointestinal Dysmotility Market Size and growth rate 2025 to 2029: Graph

What Is The Autoimmune Gastrointestinal Dysmotility Market Size 2025 And Growth Rate?

The autoimmune gastrointestinal dysmotility market size has grown strongly in recent years. It will grow from $1.73 billion in 2024 to $1.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing unawareness of rare diseases, rise in underdeveloped diagnostic practices, increasing cases of misdiagnosis with other gi disorders, rise in unavailability of targeted therapies, and increasing delays in research progress.

What Is The Autoimmune Gastrointestinal Dysmotility Market Growth Forecast?

The autoimmune gastrointestinal dysmotility market size is expected to see strong growth in the next few years. It will grow to $2.30 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rising autoimmune disease prevalence, improving diagnostic techniques, growing healthcare expenditure, increasing rare disease registries, and better clinician education. Major trends in the forecast period include technology advancements in diagnostics, innovations in immunotherapy, development of neurogastroenterology research, research and development in motility modulators, and personalized treatment approaches.

Book your 30 minutes free consultation with our research experts

How Is The Autoimmune Gastrointestinal Dysmotility Market Segmented?

The autoimmune gastrointestinal dysmotility market covered in this report is segmented –

1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy

2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics

3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions

Subsegments:

1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics

2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy

3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals

4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training

What Is Driving The Autoimmune Gastrointestinal Dysmotility Market? Rising Prevalence Of Autoimmune Disorders Is Fueling The Market Growth Due To Increasing Incidence Of Immune-Mediated Gastrointestinal Complications

The rising prevalence of autoimmune disorders is expected to propel the growth of the autoimmune gastrointestinal dysmotility market going forward. Autoimmune diseases are conditions in which the body’s immune system mistakenly attacks its healthy cells, tissues, or organs instead of protecting them from infections and foreign substances. The rising prevalence of autoimmune disorders is primarily due to a combination of genetic susceptibility and environmental triggers, which together disrupt immune system regulation and increase the likelihood of the body attacking its own tissues. Autoimmune gastrointestinal dysmotility helps identify and manage underlying autoimmune disorders by revealing immune-mediated damage to the enteric nervous system, linking gastrointestinal symptoms to systemic autoimmune activity. For instance, in November 2024, according to a survey study among 73,241,305 in 2022 by the Versorgungsatlas.de, a Germany-based organization, around 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61. Therefore, the rising prevalence of autoimmune disorders is driving the growth of the autoimmune gastrointestinal dysmotility market.

What Is Driving The Autoimmune Gastrointestinal Dysmotility Market? Increasing Focus On Personalized Medicine Is Fueling The Market Growth Due To Advancements In Tailored Treatment Approaches For Autoimmune Conditions

The increasing focus on personalized medicine is expected to propel the growth of the autoimmune gastrointestinal dysmotility market going forward. Personalized medicine refers to a medical approach that tailor’s treatment and prevention strategies to an individual’s unique genetic makeup, lifestyle, and environment. The rise of personalized medicine is primarily due to advancements in genomics, which enable precise identification of genetic variations and tailored treatments for individuals. Personalized medicine aids in the treatment of autoimmune gastrointestinal dysmotility by tailoring therapies to an individual's genetic makeup and specific disease characteristics. This approach improves treatment efficacy and minimizes side effects, offering more targeted solutions for managing complex gastrointestinal disorders. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. Therefore, the increasing focus on personalized medicine is driving the growth of autoimmune gastrointestinal dysmotility market.

Who Are The Major Players In The Global Autoimmune Gastrointestinal Dysmotility Market?

Major companies operating in the autoimmune gastrointestinal dysmotility market are AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.

What Are The Key Trends Of The Global Autoimmune Gastrointestinal Dysmotility Market? Strategic Partnerships Driving Digital Therapy Solutions In The Market

Major companies operating in the autoimmune gastrointestinal dysmotility market are focusing on adopting strategic partnerships approach to provide digital therapy solutions for managing autoimmune gastrointestinal dysmotility conditions. Strategic partnerships enhance care for autoimmune gastrointestinal dysmotility by offering integrated, virtual-first healthcare with multidisciplinary teams, improving symptom management, access to care, and cost efficiency. For instance, in March 2022, Solera Health, a US-based digital health company, partnered with Oshi Health, a US-based virtual gastrointestinal care company and Vivante Health, a US-based digital health company. This initiative will provide advanced digital therapy solutions to support the management and treatment of autoimmune gastrointestinal dysmotility. The collaboration aims to improve patient access to specialized care and enhance overall treatment effectiveness for individuals with gastrointestinal disorders.

What Is The Regional Outlook For The Global Autoimmune Gastrointestinal Dysmotility Market?

North America was the largest region in the autoimmune gastrointestinal dysmotility market in 2024. The regions covered in the autoimmune gastrointestinal dysmotility market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the autoimmune gastrointestinal dysmotility market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Autoimmune Gastrointestinal Dysmotility Market?

The autoimmune gastrointestinal dysmotility market consists of revenues earned by entities by providing services such as diagnostic testing, therapeutic treatments, clinical consultations, surgical interventions, rehabilitation and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The autoimmune gastrointestinal dysmotility market also includes sales of diagnostic kits, immunomodulatory drugs, prokinetic agents, and intravenous immunoglobulin (IVIG) therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Autoimmune Gastrointestinal Dysmotility Industry?

The autoimmune gastrointestinal dysmotility market research report is one of a series of new reports from The Business Research Company that provides autoimmune gastrointestinal dysmotility market statistics, including the autoimmune gastrointestinal dysmotility industry global market size, regional shares, competitors with the autoimmune gastrointestinal dysmotility market share, detailed autoimmune gastrointestinal dysmotility market segments, market trends, and opportunities, and any further data you may need to thrive in the autoimmune gastrointestinal dysmotility industry. This autoimmune gastrointestinal dysmotility market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Autoimmune Gastrointestinal Dysmotility Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$1.83 billion
Revenue Forecast In 2034	$2.30 billion
Growth Rate	CAGR of 5.9% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The autoimmune gastrointestinal dysmotility market covered in this report is segmented – 1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy 2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics 3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels 5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions Subsegments: 1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics 2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy 3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals 4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	AbbVie Inc., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Zeria Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Dr. Falk Pharma GmbH, Rose Pharma LLC, Parvus Therapeutics Inc., CinDome Pharma Inc., Neurogastrx Inc., Renexxion LLC, ISOThrive Inc., Ambrose Healthcare Inc., AnTolRx Inc., Enteralia Bioscience S.r.l., Immunic Inc., Mozart Therapeutics Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Autoimmune Gastrointestinal Dysmotility Market Characteristics

3. Autoimmune Gastrointestinal Dysmotility Market Trends And Strategies

4. Autoimmune Gastrointestinal Dysmotility Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Autoimmune Gastrointestinal Dysmotility Growth Analysis And Strategic Analysis Framework

5.1. Global Autoimmune Gastrointestinal Dysmotility PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Autoimmune Gastrointestinal Dysmotility Market Growth Rate Analysis

5.4. Global Autoimmune Gastrointestinal Dysmotility Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Autoimmune Gastrointestinal Dysmotility Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Autoimmune Gastrointestinal Dysmotility Total Addressable Market (TAM)

6. Autoimmune Gastrointestinal Dysmotility Market Segmentation

6.1. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Medications

Surgical Interventions

Dietary Management

Physical Therapy

6.2. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Prokinetic Agents

Anti-Inflammatory Drugs

Immunosuppressive Drugs

Antibiotics

6.3. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Gastroparesis

Chronic Intestinal Pseudo-Obstruction (Cipo)

Functional Dyspepsia

Irritable Bowel Syndrome (Ibs)

Celiac Disease

6.4. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacies

Other Distribution Channels

6.5. Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Clinics

Home Care Settings

Research Institutions

6.6. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Immunosuppressants

Corticosteroids

Prokinetic Agents

Antiemetics

Antispasmodics

Antibiotics

6.7. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Gastrostomy

Jejunostomy

Colostomy

Ileostomy

Pyloroplasty

Colectomy

6.8. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Dietary Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Enteral Nutrition

Parenteral Nutrition

Gluten-Free Diet

Elemental Diet

Small Frequent Meals

6.9. Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Pelvic Floor Therapy

Abdominal Massage Therapy

Neuromuscular Electrical Stimulation (NMES)

Biofeedback Therapy

Respiratory Muscle Training

Postural Training

7. Autoimmune Gastrointestinal Dysmotility Market Regional And Country Analysis

7.1. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Autoimmune Gastrointestinal Dysmotility Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market

8.1. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Autoimmune Gastrointestinal Dysmotility Market

9.1. China Autoimmune Gastrointestinal Dysmotility Market Overview

9.2. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Autoimmune Gastrointestinal Dysmotility Market

10.1. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Autoimmune Gastrointestinal Dysmotility Market

11.1. Japan Autoimmune Gastrointestinal Dysmotility Market Overview

11.2. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Autoimmune Gastrointestinal Dysmotility Market

12.1. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Autoimmune Gastrointestinal Dysmotility Market

13.1. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Autoimmune Gastrointestinal Dysmotility Market

14.1. South Korea Autoimmune Gastrointestinal Dysmotility Market Overview

14.2. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Autoimmune Gastrointestinal Dysmotility Market

15.1. Western Europe Autoimmune Gastrointestinal Dysmotility Market Overview

15.2. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Autoimmune Gastrointestinal Dysmotility Market

16.1. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Autoimmune Gastrointestinal Dysmotility Market

17.1. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Autoimmune Gastrointestinal Dysmotility Market

18.1. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Autoimmune Gastrointestinal Dysmotility Market

19.1. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Autoimmune Gastrointestinal Dysmotility Market

20.1. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market

21.1. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market Overview

21.2. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Autoimmune Gastrointestinal Dysmotility Market

22.1. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Autoimmune Gastrointestinal Dysmotility Market

23.1. North America Autoimmune Gastrointestinal Dysmotility Market Overview

23.2. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Autoimmune Gastrointestinal Dysmotility Market

24.1. USA Autoimmune Gastrointestinal Dysmotility Market Overview

24.2. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Autoimmune Gastrointestinal Dysmotility Market

25.1. Canada Autoimmune Gastrointestinal Dysmotility Market Overview

25.2. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Autoimmune Gastrointestinal Dysmotility Market

26.1. South America Autoimmune Gastrointestinal Dysmotility Market Overview

26.2. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Autoimmune Gastrointestinal Dysmotility Market

27.1. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Autoimmune Gastrointestinal Dysmotility Market

28.1. Middle East Autoimmune Gastrointestinal Dysmotility Market Overview

28.2. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Autoimmune Gastrointestinal Dysmotility Market

29.1. Africa Autoimmune Gastrointestinal Dysmotility Market Overview

29.2. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Autoimmune Gastrointestinal Dysmotility Market Competitive Landscape And Company Profiles

30.1. Autoimmune Gastrointestinal Dysmotility Market Competitive Landscape

30.2. Autoimmune Gastrointestinal Dysmotility Market Company Profiles

30.2.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Autoimmune Gastrointestinal Dysmotility Market Other Major And Innovative Companies

31.1. Zeria Pharmaceutical Co. Ltd.

31.2. Ironwood Pharmaceuticals Inc.

31.3. Vanda Pharmaceuticals Inc.

31.4. Dr. Falk Pharma GmbH

31.5. Rose Pharma LLC

31.6. Parvus Therapeutics Inc.

31.7. CinDome Pharma Inc.

31.8. Neurogastrx Inc.

31.9. Renexxion LLC

31.10. ISOThrive Inc.

31.11. Ambrose Healthcare Inc.

31.12. AnTolRx Inc.

31.13. Enteralia Bioscience S.r.l.

31.14. Immunic Inc.

31.15. Mozart Therapeutics Inc.

32. Global Autoimmune Gastrointestinal Dysmotility Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Autoimmune Gastrointestinal Dysmotility Market

34. Recent Developments In The Autoimmune Gastrointestinal Dysmotility Market

35. Autoimmune Gastrointestinal Dysmotility Market High Potential Countries, Segments and Strategies

35.1 Autoimmune Gastrointestinal Dysmotility Market In 2029 - Countries Offering Most New Opportunities

35.2 Autoimmune Gastrointestinal Dysmotility Market In 2029 - Segments Offering Most New Opportunities

35.3 Autoimmune Gastrointestinal Dysmotility Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Dietary Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Autoimmune Gastrointestinal Dysmotility Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Global Autoimmune Gastrointestinal Dysmotility Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: Asia-Pacific, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: China, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: India, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Japan, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Australia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Indonesia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: South Korea, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Western Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: UK, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Germany, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: France, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Italy, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Spain, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Eastern Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: Russia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: North America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: USA, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Canada, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: South America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Brazil, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Middle East, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Africa, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 80: AbbVie Inc. Financial Performance

Table 81: GlaxoSmithKline plc Financial Performance

Table 82: Takeda Pharmaceutical Company Limited Financial Performance

Table 83: Teva Pharmaceutical Industries Ltd. Financial Performance

Table 84: Chugai Pharmaceutical Co. Ltd. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Autoimmune Gastrointestinal Dysmotility Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Surgical Interventions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Dietary Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Autoimmune Gastrointestinal Dysmotility Market, Sub-Segmentation Of Physical Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Autoimmune Gastrointestinal Dysmotility Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Global Autoimmune Gastrointestinal Dysmotility Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: Asia-Pacific, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: China, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: India, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Japan, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Australia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Indonesia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: South Korea, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Western Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: UK, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Germany, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: France, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Italy, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Spain, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Eastern Europe, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: Russia, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: North America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: USA, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Canada, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: South America, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Brazil, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Middle East, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Africa, Autoimmune Gastrointestinal Dysmotility Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 80: AbbVie Inc. Financial Performance

Figure 81: GlaxoSmithKline plc Financial Performance

Figure 82: Takeda Pharmaceutical Company Limited Financial Performance

Figure 83: Teva Pharmaceutical Industries Ltd. Financial Performance

Figure 84: Chugai Pharmaceutical Co. Ltd. Financial Performance

How is the Anti-Aging Market Poised for Growth: Trends and Opportunities Through 2034

What’s Driving Growth in the Anticoagulants Market? Insights into Key Trends and Opportunities

Comprehensive Analysis of the Biomarkers Market 2025-2034: Growth Rates, Trends, and Future Opportunities

How Will the Botanical Supplements Market Grow? Key Trends and Opportunities for 2025 and Beyond

Cancer Immunotherapy Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

Comprehensive Analysis of the Compression Therapy Market 2025-2034: Growth Rates, Trends, and Future Opportunities

Unlocking the Future of the Contraceptives Market: Growth Rate, Key Trends, and Opportunities for 2025-2034

Contract Development Manufacturing Organizations Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities

Autoimmune Disease Diagnosis Market 2022 – By Product (Consumables And Assay Kits, Instruments), By End User (Clinical Laboratories, Hospitals), By Test Type (Routine Laboratory Tests, Autoantibodies Tests, Immunologic Tests, Other Tests), And By Region, Opportunities And Strategies – Global Forecast To 2031

View Report

Autoimmune Treatment Global Market Report 2025 – By Product (Consumables and Assay Kits, Instruments, Services), By Service Type (Consultation and Diagnosis, Therapy and monitoring, Drug development), By Disease (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome, Thyroiditis, Scleroderma, Other Diseases), By Drug Class (Anti-Inflammatory, Anti-Hyperglycemic, NSAIDs, Interferons, Other Drug Class), By End User (Clinical Laboratories, Hospitals, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Diabetic Gastroparesis Treatment Global Market Report 2025 – By Treatment (Medication, Surgery), By Route Of Administration (Oral, Injectables), By Indication (Compensated Gastroparesis, Gastric Failure), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Gastroesophageal Reflux Disease (GERD) Global Market Report 2025 – By Drug Type (Antacids, Proton Pump Inhibitors, H2 Receptor Blocker, Pro Kinetic Agents, Dopamine Receptor Antagonist, EndoCinch, Stretta, EsophyX, Transoral Incisionless Fundoplication (TIF)), By Procedure (Invasive, Minimally Invasive), By End-Users (Hospital, Homecare, Specialty Clinics) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Esophagoscopes And Gastroscopes Global Market Report 2025 – By Type (Rigid, Flexible, Transnasal, Other Types), By Application (Gastroesophageal Reflux Disease, Ulcers, Barrett's Esophagus, Celiac Disease, Other Applications), By End User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Diagnostic Centers, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Gastrointestinal Stromal Tumor Global Market Report 2025 – By Treatment Type (Chemotherapy, Targeted Therapy, Other Treatment Types), By Indication (Stomach, Small Intestine, Others Indications), By End-User (Hospitals, Clinics, Specialized Cancer Treatment Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Autoimmune Disease Diagnosis Global Market Report 2025 – By Product (Consumables And Assay Kits, Instruments), By End User (Clinical Laboratories, Hospitals, Others), By Test Type (Routine Laboratory Tests, Autoantibodies Tests, Immunologic Tests, Other Tests) – Market Size, Trends, And Global Forecast 2025-2034

View Report

G-CSF (Granulocyte Colony Stimulating Factors) Market 2021 - By Type (Pegfilgrastim, Filgrastim, Lenograstim), By Application (Oncology, Blood Disorders, Chronic and Autoimmune Disorders), And By Region, Opportunities And Strategies – Global Forecast To 2030

View Report

Frequently Asked Questions

What is the definition of the Autoimmune Gastrointestinal Dysmotility market?

How will the Autoimmune Gastrointestinal Dysmotility market drivers and restraints affect the market dynamics? What forces will shape the Autoimmune Gastrointestinal Dysmotility industry going forward?

The Autoimmune Gastrointestinal Dysmotility market major growth driver - Rising Prevalence Of Autoimmune Disorders Is Fueling The Market Growth Due To Increasing Incidence Of Immune-Mediated Gastrointestinal Complications. For further insights on the Autoimmune Gastrointestinal Dysmotility market, request a sample here

What is the forecast market size or the forecast market value of the Autoimmune Gastrointestinal Dysmotility market?

The Autoimmune Gastrointestinal Dysmotility market size has grown strongly in recent years. The autoimmune gastrointestinal dysmotility market size has grown strongly in recent years. It will grow from $1.73 billion in 2024 to $1.83 billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to increasing unawareness of rare diseases, rise in underdeveloped diagnostic practices, increasing cases of misdiagnosis with other gi disorders, rise in unavailability of targeted therapies, and increasing delays in research progress. The autoimmune gastrointestinal dysmotility market size is expected to see strong growth in the next few years. It will grow to $2.30 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rising autoimmune disease prevalence, improving diagnostic techniques, growing healthcare expenditure, increasing rare disease registries, and better clinician education. Major trends in the forecast period include technology advancements in diagnostics, innovations in immunotherapy, development of neurogastroenterology research, research and development in motility modulators, and personalized treatment approaches. For further insights on the Autoimmune Gastrointestinal Dysmotility market, request a sample here

How is the Autoimmune Gastrointestinal Dysmotility market segmented?

The autoimmune gastrointestinal dysmotility market covered in this report is segmented –
1) By Treatment Type: Medications, Surgical Interventions, Dietary Management, Physical Therapy
2) By Drug Class: Prokinetic Agents, Anti-Inflammatory Drugs, Immunosuppressive Drugs, Antibiotics
3) By Disease Type: Gastroparesis, Chronic Intestinal Pseudo-Obstruction (Cipo), Functional Dyspepsia, Irritable Bowel Syndrome (Ibs), Celiac Disease
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels
5) By End User: Hospitals, Clinics, Home Care Settings, Research Institutions
Subsegments:
1) By Medications: Immunosuppressants, Corticosteroids, Prokinetic Agents, Antiemetics, Antispasmodics, Antibiotics
2) By Surgical Interventions: Gastrostomy, Jejunostomy, Colostomy, Ileostomy, Pyloroplasty, Colectomy
3) By Dietary Management: Enteral Nutrition, Parenteral Nutrition, Gluten-Free Diet, Elemental Diet, Small Frequent Meals
4) By Physical Therapy: Pelvic Floor Therapy, Abdominal Massage Therapy, Neuromuscular Electrical Stimulation (NMES), Biofeedback Therapy, Respiratory Muscle Training, Postural Training For further insights on the Autoimmune Gastrointestinal Dysmotility market, request a sample here

Which region has the largest share of the Autoimmune Gastrointestinal Dysmotility market? What are the other regions covered in the report?

Who are the major players in the Autoimmune Gastrointestinal Dysmotility market?

What are the key trends in the Autoimmune Gastrointestinal Dysmotility market?

Major trends in the Autoimmune Gastrointestinal Dysmotility market include Strategic Partnerships Driving Digital Therapy Solutions In The Market. For further insights on the Autoimmune Gastrointestinal Dysmotility market, request a sample here.

What are the major opportunities in the Autoimmune Gastrointestinal Dysmotility market? What are the strategies for the Autoimmune Gastrointestinal Dysmotility market?

For detailed insights on the major opportunities and strategies in the Autoimmune Gastrointestinal Dysmotility market, request a sample here.

How does the Autoimmune Gastrointestinal Dysmotility market relate to the overall economy and other similar markets?

For detailed insights on Autoimmune Gastrointestinal Dysmotility's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Autoimmune Gastrointestinal Dysmotility industry?

For detailed insights on the mergers and acquisitions in the Autoimmune Gastrointestinal Dysmotility industry, request a sample here.

What are the key dynamics influencing the Autoimmune Gastrointestinal Dysmotility market growth? SWOT analysis of the Autoimmune Gastrointestinal Dysmotility market.

For detailed insights on the key dynamics influencing the Autoimmune Gastrointestinal Dysmotility market growth and SWOT analysis of the Autoimmune Gastrointestinal Dysmotility industry, request a sample here.

Autoimmune Gastrointestinal Dysmotility Global Market Report 2025

Autoimmune Gastrointestinal Dysmotility Global Market Report 2025

Market Insights

Related Reports

What Is Covered Under Autoimmune Gastrointestinal Dysmotility Market?

What Is The Autoimmune Gastrointestinal Dysmotility Market Size 2025 And Growth Rate?

What Is The Autoimmune Gastrointestinal Dysmotility Market Growth Forecast?

How Is The Autoimmune Gastrointestinal Dysmotility Market Segmented?

What Is Driving The Autoimmune Gastrointestinal Dysmotility Market? Rising Prevalence Of Autoimmune Disorders Is Fueling The Market Growth Due To Increasing Incidence Of Immune-Mediated Gastrointestinal Complications

What Is Driving The Autoimmune Gastrointestinal Dysmotility Market? Increasing Focus On Personalized Medicine Is Fueling The Market Growth Due To Advancements In Tailored Treatment Approaches For Autoimmune Conditions

Who Are The Major Players In The Global Autoimmune Gastrointestinal Dysmotility Market?

What Are The Key Trends Of The Global Autoimmune Gastrointestinal Dysmotility Market? Strategic Partnerships Driving Digital Therapy Solutions In The Market

What Is The Regional Outlook For The Global Autoimmune Gastrointestinal Dysmotility Market?

What Defines the Autoimmune Gastrointestinal Dysmotility Market?

How is Market Value Defined and Measured?

What is the Market Assessment and Strategic Outlook for the Autoimmune Gastrointestinal Dysmotility Industry?

Table Of Contents

List Of Tables

List Of Figures

How is the Anti-Aging Market Poised for Growth: Trends and Opportunities Through 2034

What’s Driving Growth in the Anticoagulants Market? Insights into Key Trends and Opportunities

Comprehensive Analysis of the Biomarkers Market 2025-2034: Growth Rates, Trends, and Future Opportunities

How Will the Botanical Supplements Market Grow? Key Trends and Opportunities for 2025 and Beyond

Cancer Immunotherapy Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

Comprehensive Analysis of the Compression Therapy Market 2025-2034: Growth Rates, Trends, and Future Opportunities

Unlocking the Future of the Contraceptives Market: Growth Rate, Key Trends, and Opportunities for 2025-2034

Contract Development Manufacturing Organizations Market Analysis: Key Insights on Growth Rates, Trends, and Major Opportunities

G-CSF (Granulocyte Colony Stimulating Factors) Market 2021 - By Type (Pegfilgrastim, Filgrastim, Lenograstim), By Application (Oncology, Blood Disorders, Chronic and Autoimmune Disorders), And By Region, Opportunities And Strategies – Global Forecast To 2030

Frequently Asked Questions